date,title,source
Oct-18-18,"Detailed Research: Economic Perspectives on Control4, REGENXBIO, Ferro, Kadmon, Hemispherx BioPharma, and Murphy Oil  What Drives Growth in Today's Competitive Landscape",GlobeNewswire
Oct-22-18,REGENXBIO Announces Exclusive Worldwide License with Ultragenyx for the Treatment of CDKL5 Deficiency Disorder Using NAV Vectors,PR Newswire
Oct-26-18,REGENXBIO Announces Additional Positive Interim Phase I Trial Update for RGX-314 for the Treatment of Wet AMD at the American Academy of Ophthalmology 2018 Annual Meeting,PR Newswire
Oct-29-18,ANIK vs. RGNX: Which Stock Should Value Investors Buy Now?,Zacks
Oct-31-18,REGENXBIO to Host Conference Call on November 7 to Discuss Third Quarter 2018 Financial Results and Recent Operational Highlights,PR Newswire
Nov-05-18,REGENXBIO and Abeona Therapeutics Announce Worldwide Exclusive Licenses for the Treatment of Four Rare Lysosomal Storage Disorders Using NAV AAV9 Vector,PR Newswire
Nov-06-18,REGENXBIO to Present at Upcoming Investor Conferences,PR Newswire
Nov-07-18,Regenxbio: 3Q Earnings Snapshot,Associated Press
Nov-07-18,This Rockville biotech is expanding to a new HQ. Here are the details.,American City Business Journals
Nov-07-18,REGENXBIO Reports Third Quarter 2018 Financial and Operating Results and Announces Initiation of Phase I/II Clinical Trial for RGX-121 for the Treatment of MPS II,PR Newswire
Nov-07-18,"Alexandria Real Estate Equities, Inc. Announces Development of New Build-to-Suit at the Alexandria Life Science and Translational Research Center at 9800 Medical Center Drive with Signing of 15-Year, 132,000 RSF Lease for REGENXBIO's New HQ and R&D Facility",PR Newswire
Nov-12-18,"Consolidated Research: 2018 Summary Expectations for Murphy Oil, REGENXBIO, CRA International,Inc, Carriage Services, CONMED, and BioDelivery Sciences International  Fundamental Analysis, Key Performance Indications",GlobeNewswire
Nov-13-18,Edited Transcript of RGNX earnings conference call or presentation 7-Nov-18 9:30pm GMT,Thomson Reuters StreetEvents
Nov-14-18,FDA Grants Orphan Drug Designation To RGX-181 Gene Therapy For The Treatment Of CLN2 Form Of Batten Disease,PR Newswire
